Wave Life Sciences Stock Plummets 20% Despite Positive Clinical Trial Results
Wave Life Sciences shares tumbled 22% in pre-market trading after releasing updated Phase 1b/2a trial data for its AATD treatment candidate WVE-006. The biotech firm reported statistically significant RNA editing results, with all treated patients achieving therapeutic serum AAT levels sufficient to reduce liver and lung disease risks.
CEO Paul Bolno emphasized the platform's strength, noting upcoming clinical advancements to be detailed at the company's fall Research Day. The market reaction contrasts sharply with the positive clinical outcomes, highlighting investor skepticism about biotech milestones.